We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

DNA2.0 Expands European Presence by Opening UK Office

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

DNA2.0 has announced the expansion of the company’s European operations with the creation of the United Kingdom-based DNA2.0 Ltd.

Michael Dyson, PhD, has been appointed as Managing Director of European Operations and will lead the new venture in the UK as well as DNA2.0’s established office in Basel, Switzerland.

“The opening of our UK headquarters represents a major step in our global growth,” said Jeremy Minshull, President of DNA2.0. “Even in a time of economic uncertainty, the market for gene synthesis and its many applications continues to grow rapidly in Europe. We are confident that European customers will continue to seek out our world-class customer support, fast and reliable turnaround time and the certainty that their intellectual property is completely protected.”

The Company says that, while many other gene synthesis companies offshore manufacturing to areas of the world with lax IP protection, all DNA2.0 genes are made at the company’s facility in Menlo Park, thus ensuring the greatest security for patented or confidential sequences. DNA2.0’s two European locations ensure that European customers receive the same PhD-level service and support as their US counterparts.

“The demand in the European marketplace for high quality synthetic genes, delivered quickly and with confidence, is tremendous,” said Dr. Dyson. “We look forward to serving our European customers even more effectively through this new base of operations.”